3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Dermatologic
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
104
Lymphoma, Large B-Cell, Diffuse
81
Leukemia, Myeloid, Acute
75
Multiple Myeloma
71
Breast Neoplasms
70
Lymphoma, Non-Hodgkin
62
Lymphoma
62
Leukemia, Lymphocytic, Chronic, B-Cell
53
Burkitt Lymphoma
53
Recurrence
51
Myelodysplastic Syndromes
50
Lymphoma, Follicular
49
Lymphoma, B-Cell
48
Leukemia
43
Triple Negative Breast Neoplasms
40
Lymphoma, Mantle-Cell
38
Neoplasms
37
Melanoma
34
Hodgkin Disease
34
Lymphoma, B-Cell, Marginal Zone
32
Hematologic Neoplasms
31
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
29
Neuroblastoma
28
Ovarian Neoplasms
26
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
22
Neoplasm Metastasis
22
Pancreatic Neoplasms
21
Leukemia, Biphenotypic, Acute
21
Sarcoma
18
Myeloproliferative Disorders
17
Interventions
Imatinib Mesylate
12
Sunitinib
10
ripretinib
5
regorafenib
4
Blood Specimen Collection
3
envafolimab
2
Specimen Handling
2
Paclitaxel
2
Magnetic Resonance Spectroscopy
2
IDRX-42
2
Biopsy
2
trastuzumab deruxtecan
1
spartalizumab
1
ribociclib
1
pemigatinib
1
palbociclib
1
olverembatinib
1
nilotinib
1
guadecitabine
1
binimetinib
1
avelumab
1
avapritinib
1
atezolizumab
1
apatinib
1
Temozolomide
1
TAS-116
1
Surgical Instruments
1
Sorafenib
1
Rogaratinib
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Stromal Tumors
×
Cyclophosphamide
×
1 year
×
Clear all
NCT01046487
2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1
Completed
26 enrolled